Posted by Michael Wonder on 08 Mar 2019
Decision to make changes to funded haemophilia treatments
8 March 2019 - PHARMAC is pleased to announce changes to funded haemophilia treatments that will result in two new extended half-life treatments being funded for the first time in New Zealand.
These extended half-life treatments will be funded for all people requiring prophylaxis treatment and are expected to provide prolonged protection from bleeding and reduce the number of intravenous injections required.
Changes are also being made to the funding arrangements of the currently funded short half-life treatments and bypassing agents.
The changes will be implemented over a six-month transition period, commencing on 1 May 2019.
